Dianthus Therapeutics, Inc. is headquartered in New York City. The company is focused on developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Live webcasts of the Company’s presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

Triumphantly positioned next to her twin sister Jessica Parry as the other half of progressive metal outfit Dianthus, Parry has taken the world by storm over the last year. But Parry isn’t only ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), ...

Follow our easy guide to taking cuttings and you can create a summer display of your favourite variety of dianthus. A cottage garden favourite, pinks are easy to grow and look good at the front of ...

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Option Chain is currently not available. Nasdaq provides call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's ...